scholarly journals Blood Glucose – Lowering Potentials of Annona muricata Leaf Extract in Alloxan–Induced Diabetic Rats

2021 ◽  
Vol 2 (2) ◽  
pp. 106-113
Author(s):  
P. O. Opara ◽  
V. H. A. Enemor ◽  
F. U. Eneh ◽  
F. C. Emengaha
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Leaf Extract ◽  
Phytochemical Analysis ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Group 6 ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

The blood glucose- lowering potentials of ethanol leaf extract of Annona muricata were studied. Thirty wistar albino rats were divided into six groups of five rats per group. Group 1 served as “Normal control” animals and received normal rat pellets and water. Diabetes mellitus was induced in Groups 2, 3, 4, and 5 by intraperitoneal injection of alloxan (130 mg/kg). Group 6 rats were administered with 400 mg/kg daily of the extract without induction; group 3 rats were treated with glibenclamide (5 mg/kg body weight), groups 4 and 5 received 200 mg/kg and 400 mg/kg body weight of A. muricata leaf extract daily respectively throughout the duration of the experiment of 14 days. Group 2 rats were induced but not treated with any drug, thus it served as the “Negative control” group. Quantitative phytochemical analysis of the leaf extract was carried out using the Association of Official Analytical Chemists (AOAC) methods. Acute toxicity test of the leaf extract of A. muricata was determined using 12 rats by Lorke’s toxicity testing method. The blood glucose levels of the animals in each group were determined using Accu-chek test strip method. The weights of the animals were determined using a standard electronic weighing balance. The result of the quantitative phytochemical analysis of the leaf showed that the ethanol leaf extract contains the following: phenols (74 mg/100 g), flavonoids (3.70 mg/100 g), tannins (2.95 mg/100 g), oxalate (6.48 mg/100 g), terpenoid (13.88 mg/100 g), phytates (130 mg/100 g), saponins (6800 mg/100 g), alkaloids (570 mg/100 g), cardiac glycoside (1690 mg/100g). Acute toxicity studies showed that LD50 was 3807.89 mg/kg body weight. The results of the average blood glucose levels (mg/dl) of the rats in each group were group 1, 82.6071±7.7524, group 2, 309.3571±163.6923, group 3, 226.7143±132.8182, group 4, 146.5000±140.1465, group 5, 150.4783±81.8340, and group 6, 83.4643±12.5329 for each group respectively. The average body weights of the rats in each group were group 1, 192.8571±22.5844, group 2, 185.7143±33.6759, group 3, 177.1429±36.67500, group 4, 219.2857±21.2908, group 5, 119.5455±23.5993, and group 6, 191.7857±25.2475. The findings from this study suggest that ethanolic leaf extract of A. muricata has notable effect in lowering blood glucose levels in diabetic rats and is a more potent drug in the treatment and management of diabetes mellitus and oxidative stress- related diseases.

scholarly journals Clinical Outcomes of Non-diabetic COVID-19 Patients with Different Blood Glucose Levels: A Nationwide Turkish Study (TurCoGlycemia)

2021 ◽  
Author(s):  
Cem Haymana ◽  
Ibrahim Demirci ◽  
Ilker Tasci ◽  
Erman Cakal ◽  
Serpil Salman ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Blood Glucose ◽  
Diabetic Patients ◽  
Icu Admission ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Group 3 ◽  
Group 2 ◽  
Health Database ◽  
Group 1

Abstract Purpose New coronavirus disease 2019 (COVID-19) has a worse prognosis in patients with diabetes. However, there are insufficient data about the effect of hyperglycemia on COVID-19 prognosis in non-diabetic patients. This study aimed to investigate the relationship between random blood glucose levels measured at the time of diagnosis and prognosis of COVID-19 disease in non-diabetic patients. Methods A nationwide retrospective cohort of non-diabetic patients with confirmed COVID-19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated. The patients were stratified into three groups according to blood glucose levels which were <100 mg/dL in group-1, in the range of 100-139 mg/dl in group-2, and the range of 140-199 mg/dl in group-3. Clinical characteristics and outcomes were compared among the groups. The primary outcome was mortality. Results A total of 12,817 non-diabetic patients (median age [IQR]: 44 [25] years, females: 50.9%) were included. Patients in group-2 (5%) and group-3 (14%) had higher mortality rates than patients in group-1 (2.1%). The rates of hospitalization, hospital stays longer than 8 days, intensive care unit (ICU) admission, ICU stay more than 6 days, and mechanical ventilation were also significantly higher in group-3 patients. Likewise, glucose levels in the range of 140-199 mg/dL were an independent associate of mortality and composite of ICU admission and/or mechanical ventilation. ConclusionHyperglycemia at the time of COVID-19 diagnosis is associated with poor prognosis in non-diabetic patients. Clinicians should be more careful in the treatment of non-diabetic COVID-19 patients with hyperglycemia.

scholarly journals Uji Efek Antidiabetik Ekstrak Daun Trembesi (Albizia saman (Jacq.) Merr) Terhadap Mencit (Mus musculus L)

WARTA FARMASI ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 43-52
Author(s):  
Muhammad Azdar Setiawan ◽  
Muhammad Syaiful Saehu ◽  
Kartini Kartini
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Mus Musculus ◽  
Leaf Extract ◽  
Positive Control ◽  
Negative Control ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Reduce Blood Glucose ◽  
Albizia Saman

ABSTRAK Daun trembesi (Albizia saman (Jacq.) Merr) adalah salah satu tanaman berkhasiat menurunkan kadar glukosa darah dimana kandungan kimianya berpotensi menurunkan kadar glukosa darah antara lain flavonoid yang bekerja dengan cara menstimulasi sel- sel beta dari pulau langerhans, sehingga sekresi insulin ditingkatkan.Penelitian ini bertujuan untuk mengetahui efek antidiabetes ekstrak daun trembesi (Albizia saman (Jacq.) Merr) pada mencit (Mus musculus). Metode Penelitian ini merupakan penelitian Eksperimen dimana sebanyak 20 ekor mencit dibuat diabetes dengan menggunakan Streptozotosin 150 mg/kgBB secara Intraperitonial. Kemudian dibagi menjadi 5 kelompok perlakuan, yaitu: Ekstrak dosis 25 mg/kgBB, 50 mg/kgBB, 100  mg/kgBB, sebagai kontrol positif Glibenclamid 5 mg dan kontrol negatif suspensi Na.CMC 0,5%. Data yang diperoleh dianalisis dengan uji ANOVA. Hasil analisa statistik menunjukan pada konsentrasi ekstrak 100 mg/kgBB memberikan efek yang optimum dengan perlakuan kontrol positif Glibenklamid.  Kata Kunci  : Ekstrak Daun Trembesi, Antidiabetik.  ABSTRACT Trembesi leaf (Albizia saman (Jacq.) Merr) is one of the efficacious plants to reduce blood glucose levels where the chemical content has the potential to reduce blood glucose levels, among others, flavonoids that work by stimulating beta cells of the island langerhans, so that insulin secretion is increased. It aims to determine the antidiabetic effect of trembesi leaf extract (Albizia saman (Jacq.) Merr) in mice (Mus musculus). This research method is an experimental study in which as many as 20 mice were made diabetic using Streptozotosin 150 mg / kgBW intraperitonially. Then divided into 5 treatment groups, namely: Extract dose 25 mg / kg body weight, 50 mg / kg body weight, 100 mg / kg body weight, as positive control Glibenclamid 5 mg and negative control suspension Na.CMC 0.5%. The data obtained were analyzed by ANOVA test. The results of statistical analysis showed that the extract concentration of 100 mg / kgBB gave the optimum effect with the positive control of Glibenclamide. Keywords: Trembesi Leaf Extract, Antidiabetic.

INSIGHT OF METHANOLIC EXTRACT OF VENTILAGO MADERASPATANA LEAVES ON HEPATOPROTECTIVE ACTIVITY UNDER STREPTOZOTOCIN-INDUCED DIABETIC RATS

2020 ◽  
pp. 73-76
Author(s):  
VENUGOPAL REDDY B ◽  
RAMANA REDDY M ◽  
VENKATA SUBBAIAH G ◽  
SATHYAVELU REDDY K
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Leaf Extract ◽  
Methanolic Extract ◽  
Hepatoprotective Activity ◽  
Positive Control ◽  
Diabetic Rats ◽  
Glucose Levels ◽  
Blood Glucose Levels

Objective: The methanolic leaf extract of Ventilago maderaspatana (MEVML, 200 mg/kg body weight [b.w.]) was investigate to hepatoprotective activity under streptozotocin-induced (45 mg/kg b.w.) diabetic (Di) rats. Methods: In the present study, we determined the blood glucose levels, b.w., insulin, creatinine, and bilirubin levels in normal, Di, Di treated with MEVML and positive control rats. Results: The Di rats shown adverse changes in blood glucose levels, b.w., insulin, creatinine, and bilirubin levels when compared to other group rats. Reverse the adverse changes in the above parameters when treated the Di rats with MEVML Conclusion: The MEVML shown anti-diabetic activity and reverse the adverse changes in the above parameters in liver so that the MEVML supported the traditional claim of the hepatoprotective activity under Di condition.

scholarly journals Early Blood Glucose Level Post-Admission Correlates with the Outcomes and Oxidative Stress in Neonatal Hypoxic-Ischemic Encephalopathy

Antioxidants ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 39
Author(s):  
Inn-Chi Lee ◽  
Jiann-Jou Yang ◽  
Ying-Ming Liou
Keyword(s):  
Blood Glucose ◽  
Glucose Level ◽  
Clinical Staging ◽  
Mri Findings ◽  
Neurodevelopmental Outcomes ◽  
Glucose Levels ◽  
Group 3 ◽  
Group 2 ◽  
Poor Outcomes ◽  
Group 1

The antioxidant defense system is involved in the pathogenesis of neonatal hypoxic-ischemic encephalopathy (HIE). To analyze the relationship between first serum blood glucose levels and outcomes in neonatal HIE, seventy-four patients were divided, based on the first glucose level, into group 1 (>0 mg/dL and <60 mg/dL, n =11), group 2 (≥60 mg/dL and <150 mg/dL, n = 49), and group 3 (≥150 mg/dL, n = 14). Abnormal glucose levels had poor outcomes among three groups in terms of the clinical stage (p = 0.001), brain parenchymal lesion (p = 0.004), and neurodevelopmental outcomes (p = 0.029). Hearing impairment was more common in group 3 than in group 1 (p = 0.062) and group 2 (p = 0.010). The MRI findings of group 3 exhibited more thalamus and basal ganglion lesions than those of group 1 (p = 0.012). The glucose level was significantly correlated with clinical staging (p< 0.001), parenchymal brain lesions (p = 0.044), hearing impairment (p = 0.003), and neurodevelopmental outcomes (p = 0.005) by Pearson’s test. The first blood glucose level in neonatal HIE is an important biomarker for clinical staging, MRI findings, as well as hearing and neurodevelopment outcomes. Hyperglycemic patients had a higher odds ratio for thalamus, basal ganglia, and brain stem lesions than hypoglycemic patients with white matter and focal ischemic injury. Hyperglycemia can be due to prolonged or intermittent hypoxia and can be associated with poor outcomes.

scholarly journals Determination of antidiabetic activity of aqueous and alcoholic senna alata leaf extract

2019 ◽  
Vol 10 (SPL1) ◽  
Author(s):  
SA Abbas ◽  
Yeoh KY ◽  
Allan Mathews ◽  
Ayesha Fatima ◽  
ABM Helaluddin
Keyword(s):  
Blood Glucose ◽  
Aqueous Extract ◽  
Antidiabetic Activity ◽  
Control Group ◽  
High Dose ◽  
Alcoholic Extract ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Group 6 ◽  
Group 2

This study is conducted to determine the antidiabetic activity capabilities of both aqueous and alcoholic extracts of Senna alata. Route of administration was by oral intubation on diabetic-induced Sprague Dawley rats through single dose intraperitoneal injection of a diabetogenic agent, Streptozotocin 55mg/kg. This study consists of 9 groups with 4 rats each, Group 1 serves as a control group, Group 2 will be treated with a standard antidiabetic drug, Metformin as a positive control, Group 3 acts as a negative control with no treatment, Group 4 to group 6 will be given aqueous extract of doses from 2 to 8g/kg and Group 7 to group 9 were treated with alcoholic extract of the same dosage strength of Group 4 to 6. Group 2 to 9 were fasted prior to the administration of STZ. Blood glucose was measured on the first two days, three times a week after administration of STZ to confirm rats have reached diabetic FBS blood glucose levels of more than 7.5mmol/L. Both aqueous and alcoholic treatments were administrated BID for a duration of 7 days, and blood glucose levels measured at 2-day intervals. There is a significant reduction (P<0.05) in blood glucose levels for Group 6, Group 8, and Group 9 when compared to Group 3 (negative control). Groups that have a significant reduction in blood glucose levels were comparable to Group 2 (positive control) but were still not as efficacious as standard drug Metformin. (p >0.05) These groups are Group 6 (high dose aqueous extract 12g/kg) and Group 9 (high dose alcohol extract 12g/kg). Groups administered with alcoholic extracts were shown to lower blood glucose levels compared to aqueous extracts. The alcoholic extract has exhibited significant higher hypoglycemic effects on STZ induced diabetic rats compared to aqueous extract. No side effects were observed during the course of treatment, even with high dosages.

Evaluation of Glucose and Lipid Lowering Activity of Arganimide A in Normal and Streptozotocin-Induced Diabetic Rats

2019 ◽  
Vol 19 (4) ◽  
pp. 503-510 ◽  
Author(s):  
Mohamed Eddouks ◽  
Farid Khallouki ◽  
Robert W. Owen ◽  
Morad Hebi ◽  
Remy Burcelin
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Oral Administration ◽  
Lipid Profile ◽  
Plasma Cholesterol ◽  
Diabetic Rats ◽  
Lipid Lowering ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Lowering Activity

Aims: Arganimide A (4,4-dihydroxy-3,3-imino-di-benzoic acid) is a compound belonging to a family of aminophenolics found in fruit of Argania spinosa. The purpose of this study was to investigate the glucose and lipid lowering activity of Arganimide A (ARG A). Methods: The effect of a single dose and daily oral administration of Arganimide A (ARG A) on blood glucose levels and plasma lipid profile was tested in normal and streptozotocin (STZ) diabetic rats at a dose of 2 mg/kg body weight. Results: Single oral administration of ARG A reduced blood glucose levels from 26.50±0.61 mmol/L to 14.27±0.73 mmol/L (p<0.0001) six hours after administration in STZ diabetic rats. Furthermore, blood glucose levels were decreased from 5.35±0.30 mmol/L to 3.57±0.17 mmol/L (p<0.0001) and from 26.50±0.61 mmol/L to 3.67±0.29 mmol/L (p<0.0001) in normal and STZ diabetic rats, respectively, after seven days of treatment. Moreover, no significant changes in body weight in normal and STZ rats were shown. According to the lipid profile, the plasma triglycerides levels were decreased significantly in diabetic rats after seven days of ARG treatment (p<0.05). Moreover, seven days of ARG A treatment decreased significantly the plasma cholesterol concentrations (p<0.001). Conclusion: ARG A possesses glucose and lipid-lowering activity in diabetic rats and this natural compound may be beneficial in the treatment of diabetes.

scholarly journals Pharmaceutical hit of anti type 2 Diabetes mellitus on the phenolic extract of Malaka (Phyllanthus emblica L.) flesh

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Musri Musman ◽  
Mauli Zakia ◽  
Ratu Fazlia Inda Rahmayani ◽  
Erlidawati Erlidawati ◽  
Safrida Safrida
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Phyllanthus Emblica ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Phenolic Extract

Abstract Background Ethnobotany knowledge in a community has shaped local wisdom in utilizing plants to treat diseases, such as the use of Malaka (Phyllanthus emblica) flesh to treat type 2 diabetes. This study presented evidence that the phenolic extract of the Malaka flesh could reduce blood sugar levels in the diabetic induced rats. Methods The phenolic extract of the P. emblica was administrated to the glucose-induced rats of the Wistar strain Rattus norvegicus for 14 days of treatment where the Metformin was used as a positive control. The data generated were analyzed by the two-way ANOVA Software related to the blood glucose level and by SAS Software related to the histopathological studies at a significant 95% confidence. Results The phenolic extract with concentrations of 100 and 200 mg/kg body weight could reduce blood glucose levels in diabetic rats. The post hoc Dunnet test showed that the administration of the extract to the rats with a concentration of 100 mg/kg body weight demonstrated a very significant decrease in blood glucose levels and repaired damaged cells better than administering the extract at a concentration of 200 mg/kg weight body. Conclusion The evidence indicated that the phenolic extract of the Malaka flesh can be utilized as anti type 2 Diabetes mellitus without damaging other organs.

scholarly journals Association between serum oestradiol level on the hCG administration day and neonatal birthweight after IVF-ET among 3659 singleton live births

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu Liu ◽  
Jing Li ◽  
Wanyu Zhang ◽  
Yihong Guo
Keyword(s):  
Birth Weight ◽  
Ovarian Stimulation ◽  
Group 4 ◽  
Group 6 ◽  
Group 3 ◽  
Group 5 ◽  
Group 2 ◽  
The Impact ◽  
Ivf Et ◽  
Group 1

AbstractOestradiol, an important hormone in follicular development and endometrial receptivity, is closely related to clinical outcomes of fresh in vitro fertilization-embryo transfer (IVF-ET) cycles. A supraphysiologic E2 level is inevitable during controlled ovarian hyper-stimulation (COH), and its effect on the outcome of IVF-ET is controversial. The aim of this retrospective study is to evaluate the association between elevated serum oestradiol (E2) levels on the day of human chorionic gonadotrophin (hCG) administration and neonatal birthweight after IVF-ET cycles. The data of 3659 infertile patients with fresh IVF-ET cycles were analysed retrospectively between August 2009 and February 2017 in First Hospital of Zhengzhou University. Patients were categorized by serum E2 levels on the day of hCG administration into six groups: group 1 (serum E2 levels ≤ 1000 pg/mL, n = 230), group 2 (serum E2 levels between 1001 and 2000 pg/mL, n = 524), group 3 (serum E2 levels between 2001 and 3000 pg/mL, n = 783), group 4 (serum E2 levels between 3001 and 4000 pg/mL, n = 721), group 5 (serum E2 levels between 4001 and 5000 pg/mL, n = 548 ), and group 6 (serum E2 levels > 5000 pg/mL, n = 852). Univariate linear regression was used to evaluate the independent correlation between each factor and outcome index. Multiple logistic regression was used to adjust for confounding factors. The LBW rates were as follows: 3.0% (group 1), 2.9% (group 2), 1.9% (group 3), 2.9% (group 4), 2.9% (group 5), and 2.0% (group 6) (P = 0.629), respectively. There were no statistically significant differences in the incidences of neonatal LBW among the six groups. We did not detect an association between peak serum E2 level during ovarian stimulation and neonatal birthweight after IVF-ET. The results of this retrospective cohort study showed that serum E2 peak levels during ovarian stimulation were not associated with birth weight during IVF cycles. In addition, no association was found between higher E2 levels and increased LBW risk. Our observations suggest that the hyper-oestrogenic milieu during COS does not seem to have adverse effects on the birthweight of offspring after IVF. Although this study provides some reference, the obstetric-related factors were not included due to historical reasons. The impact of the high estrogen environment during COS on the birth weight of IVF offspring still needs future research.

Sign in / Sign up

Export Citation Format

Share Document